{"name":"Oxford Biomedica","slug":"oxford-biomedica","ticker":"OXB","exchange":"LSE","domain":"oxb.com","description":"Oxford Biomedica (OXB) is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.","hq":"Oxford, UK","founded":1994,"employees":"977","ceo":"Frank Mathias","sector":"Gene & Cell Therapy CDMO","stockPrice":619,"stockChange":-11,"stockChangePercent":-1.75,"marketCap":"$1.0B","metrics":{"revenue":226707926.8918912,"revenueGrowth":22.5,"grossMargin":39.1,"rdSpend":0,"netIncome":-40477754.3408,"cash":130191709.6683,"dividendYield":0,"peRatio":46,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Trovax","genericName":"Trovax","slug":"trovax","indication":"Other","status":"discontinued"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Standard of care therapy","genericName":"Standard of care therapy","slug":"standard-of-care-therapy","indication":"Various cancers","status":"phase_3"}]}],"pipeline":[{"name":"Trovax","genericName":"Trovax","slug":"trovax","phase":"discontinued","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Standard of care therapy","genericName":"Standard of care therapy","slug":"standard-of-care-therapy","phase":"phase_3","mechanism":"This drug is a standard of care therapy.","indications":["Various cancers"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Oxford Biomedica reports FY 2023 results","summary":"The company reported revenue of £43.6 million and a loss of £14.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-06-15","type":"deal","headline":"Oxford Biomedica and Adaptimmune announce collaboration","summary":"The companies will collaborate on the development of a novel gene therapy for cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNRnpBbkRJbUFDUG5Ea1ZIOEFZbjJOa2I5aWlSUl9DblNDUmJRX1hxcXo2aWZ3YzgxNWdLWF9GSVRZYkZ6Ni1mZXdYZ29kSXVFanRWUnlLdUZna0hQWFkyc29OQy1DYUUwY0IyREEycWlwNklrLTNZZVVRUFYwN3RrakduWGprR0h0a0g2MkwzekZNc3laaFZ3NDhrLWxYVHpyWTNaUnNoQ3B3TmdsQndmY1huSXItU1pTWGJNQlFJTkpHSG1ERjdHSF9lZFZOWmYzbFN3?oc=5","date":"2026-03-26","type":"earnings","source":"TipRanks","summary":"Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook - TipRanks","headline":"Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNX0RidVl0S0ZtWFJfVTZWOER6a3BtdmVtUHFJR051WkM3bUdTOWhtOUE3TV9OWXg2eUJ6LUtYZnAtSTQzUlQ2U1NYYzNYWFBhWVY0ODUtdG1wcUVFWkdJSmFhUHA3OFVSWmkwVWxKUVN0TVdXMkFKUmpNcXp6VlV5NkJwZi1RYmh0cWFDeGRKdnRHb3FSQXExR0NOOU9RTUNncU8zaWJUaw?oc=5","date":"2026-03-18","type":"deal","source":"Contract Pharma","summary":"Oxford Biomedica Signs Licensing Deal with Australia’s VVMF - Contract Pharma","headline":"Oxford Biomedica Signs Licensing Deal with Australia’s VVMF","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNSkRSenZaYWtJcjRDMU85dlRobkNTaUNGekNqTWlMa1RCQ2ZOQzk4aEsta2NiYmk1eE5qYjZoUDYzNGx1RV90RzBCblo3VWFlQUVqTkItVm9scVB2VWZUZnE4MVRta3ZUVXFzbFlBNmVpS1FhQXNTb2pQY1QtVHYxUG9oM3o3MDR3eC1vN3AyUWEwTXJWdlZ4bHBGSlMzcjViUFk4eWwwSWZjRnN5YXBIY28zbw?oc=5","date":"2026-02-25","type":"pipeline","source":"Sharecast.com","summary":"EQT not planning to bid for Oxford Biomedica - Sharecast.com","headline":"EQT not planning to bid for Oxford Biomedica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQTNJU1JsdDA1RFNsQVdtV1BxeUhpSlFQU1JzeEJYS2lCcVBRSmdhS2w2MTV2Wl9CSWxRRG9rNkFGbUZZMU5NNnotUVFCeWdZVFdQLXN5RVNEVGJvSXFpeVpGT2gtUTNVaDdqUTdIUnNSMXVKa1Y0ZmtEZUpfMEIteUk0eWZpQ3htcFZNQUIyVXdsaE4tbXVTU0RraE5WZU9Qc1Z6bmhjR3kzcmNJSEJQbi1yd1dUdFMxLS1N?oc=5","date":"2026-02-25","type":"pipeline","source":"Reuters","summary":"EQT backs out of takeover bid for UK's Oxford Biomedica - Reuters","headline":"EQT backs out of takeover bid for UK's Oxford Biomedica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPeTkyaFVyUjBIbVhKaUFyQy01UFFta0xFSGFaLWh4ZVJsRF9lbnh0THZfcmVLYjFrVGdkU1lOMmVGbW12ZS1ZM29IejlGYk85ZDZLc0xIcjhtYmstRFJsazVDS2p4bHNaWUZCU25nOS00RWMzRV9WdWl0OEFsdHdBRUNwZkt6UXp3eGVPTHQ4NGVPQ1RDaUE4dFpMMDBPdDAxekI3Q01xMTAwZGJ6VHFiZFNyN2sxbVRWVXRUTENaR1l1SjNjV0pNQkI2MUtjMUVYUVo4SWJfVG9XQQ?oc=5","date":"2026-02-11","type":"pipeline","source":"Sharecast.com","summary":"Oxford Biomedica extends ‘put up or shut up’ deadline as EQT talks continue - Sharecast.com","headline":"Oxford Biomedica extends ‘put up or shut up’ deadline as EQT talks continue","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPbW1mQXluR0ZUSTZxRWdEekJBZkljQzZWLURNUnVGRUpLZlBHY3JOa2JvdUhLVkZPdktPOC11eVBBeHBuUjFKQ21TdURuaWVnLTBSdldNTUJvRXhWOHk0UDdmVXdwc1huQjJIZDZ0bHd2Z01lbS1lTXlwd2JvcVM3R0JOVm1aY0JqSlBzYWxQN0VXLWdwdHRqbWhEUmJNMm5HWjl1Vl9jWlU?oc=5","date":"2026-02-04","type":"deal","source":"Fierce Pharma","summary":"OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts - Fierce Pharma","headline":"OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUGt4c3FQX0hDVzNPaVl6clV4TFk1NGhtZXBFZWtTV1g4YjVQZ1dFLS1iVXZyWkhGd0xnVE9hVXlmMi1NUEtVUGp2QTV0SGdVUzZud3BjMkZXTkFjU3ZBbDNTc2QwNjFPQ3NOWkgyczdGay1CRTlsX3JuREVieGRrVk1LREVJYlozMGduc3hJVUlMbEdZQ19idE1JcEExdUx2c1FROFAzWFFMYjNSRzFGNnJadUppWC1Ud3ZR?oc=5","date":"2026-02-04","type":"deal","source":"Contract Pharma","summary":"OXB and BMS Expand Partnership With Lentiviral Vectors for CAR-T Programs - Contract Pharma","headline":"OXB and BMS Expand Partnership With Lentiviral Vectors for CAR-T Programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOMWhSNU5FbXBrUlhHV3pBVkhBeF9vYUFKaURZbjlnNldvUS1qd0tRbXF2VEFhTTYtSlU2THl1bFNtendaUmxWbDNabDFuOFJWR2ZWUnRwcVBqTnhnb2Rnc1lCZ1pDUDdlV0dPRUhNWC03SmVVelYwNVQ4TkFObHBhYUdzbUNTQ2JVQTU3d2Fub0VmaUNuNmQxelJleUM5RURXamJzTml2WXFGd0phTm1GeGZ0dW8tUUY2Z0VIbFVtR2xqcTZpN1pfVkZRd1ZjVlU?oc=5","date":"2026-01-15","type":"pipeline","source":"proactiveinvestors.com","summary":"Oxford BioMedica jumps after confirming takeover talks with EQT | LSE:OXB - proactiveinvestors.com","headline":"Oxford BioMedica jumps after confirming takeover talks with EQT | LSE:OXB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNdHNsYllIX25RSVI1US1PWWVXY05JZXVpTTBQVGhFSXpCWGk2QmdqVkxHSERXeGNSNE92Z21YWjBURTU3QkhkdUVpUFh5MVBXaWhNZVRacTJGQmptV2p4VDlfNnlKUjJHUzVRSVpzRWxUYy0wYVJOYlFtQ1A2T0FfNXNiOVE4N1FGREhPLXNuU0tXRXVEVmJZejJNbmlZVC1fdk10NmRueXZiMG1rcGVmRDB5X3RNakVnd3c?oc=5","date":"2025-10-07","type":"deal","source":"Fierce Pharma","summary":"OXB kicks off US expansion, buying viral vector plant in N.C. from National Resilience for $4.5M - Fierce Pharma","headline":"OXB kicks off US expansion, buying viral vector plant in N.C. from National Resilience for $4.5M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxQVkx4RHNLYW94NXRmN3gybFU0bmtnV3EycXpZUnRrRHJjcFZBRGJsZHp4QUI5aUxTMUdCdF81eXVpZl9vRG1tMVc1Y3I3TmxjWlVyWEczS1NTcjNoRmpSaUtmY3A2TUNYRlduTV8tX0xERWpzNkFrQ1dkMm54WTZEV2lEQnBUelBVYkl6SnhFMHVleC1tdUg2aWhabFA5dVZWdGJSdWlhZnFmZVd4UmdXa3M0Rm1kUHZ6bklfdDhWakRDTGFLRVJscUpjaThvZDlRcUVyZFY2UmhFWl8zU0ZYaFV1aWI1SE5rOGM3WHpvcWRSTE9HbWpqUW4xWXpfRGZrQkpj?oc=5","date":"2025-10-07","type":"pipeline","source":"globenewswire.com","summary":"OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina - globenewswire.com","headline":"OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQeHoySnFOWnpNTUR6WjhzM2p3RVF4WmdIc1ZOWkFHMzRQcDJ2MDVmZGdmNDVTY3BFQ1k5LUljdDZXQ1RnZlFqRnp4Zy0zcUlSM3NfMGkzeTA3SUZrSEg5QVQxbXhsVTF5ZHF0YkNicnhtNzdmeDlfeWEwQWptNGJVeFdQRkR6Ry1PUXpQX1FHNVNIOHZFbmMwQm15SkZLT01WcXN6Y2xrU2tFNUotaXc?oc=5","date":"2025-08-15","type":"pipeline","source":"Fierce Pharma","summary":"CDMO OXB raises £60M to support US expansion ambitions - Fierce Pharma","headline":"CDMO OXB raises £60M to support US expansion ambitions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOc2NsTmdjV05zRzFCeGkxTHA1N25QY29haTFxbWJUSmlKMndHS2lHVkNmc09rbzhNSTREYTJNdHh4djRhS242UmN0WWVfcS1nZHNaM2QtU0x2VVZ4ZzVfaEdfRGc3eXhaQUUwRHA2c1pDUTdDT2swa3I4cE9ZLV9mVnVpZzBXYU4zLUI3MTRvTS10Mmc0WV94QUl0RDNiWUQzb1p4V2pFRUI5SEU3dVNWT282WWFJbTJKcFRhRlJiS2cwRlk?oc=5","date":"2020-06-08","type":"pipeline","source":"Fierce Biotech","summary":"After 11 years, Sanofi kicks backs the rights to unwanted gene therapies to Oxford Biomedica - Fierce Biotech","headline":"After 11 years, Sanofi kicks backs the rights to unwanted gene therapies to Oxford Biomedica","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"discontinued":1,"phase_3":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Spark Therapeutics","uniQure","Sangamo Therapeutics"],"therapeuticFocus":["Gene Therapy","Cell Therapy"],"financials":{"source":"yahoo_finance","revenue":226707937.6401,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":226707937.6401},{"period":"2024-12-31","value":173042131.1017},{"period":"2023-12-31","value":120297983.46790001},{"period":"2022-12-31","value":188078875.2129}],"grossProfit":88645852.07800001,"grossProfitHistory":[{"period":"2025-12-31","value":88645852.07800001},{"period":"2024-12-31","value":71235097.3481},{"period":"2023-12-31","value":53374261.3747},{"period":"2022-12-31","value":92946479.1241}],"rdSpend":6800929.1182,"rdSpendHistory":[{"period":"2025-12-31","value":6800929.1182},{"period":"2024-12-31","value":6104982.5984000005},{"period":"2023-12-31","value":15411587.8931},{"period":"2022-12-31","value":81870449.95570001}],"sgaSpend":49386675.9099,"operatingIncome":-44281276.7299,"operatingIncomeHistory":[{"period":"2025-12-31","value":-44281276.7299},{"period":"2024-12-31","value":-58446072.402200006},{"period":"2023-12-31","value":-118376741.14490001},{"period":"2022-12-31","value":-69269518.6638}],"netIncome":-40477754.3408,"netIncomeHistory":[{"period":"2025-12-31","value":-40477754.3408},{"period":"2024-12-31","value":-58026892.259},{"period":"2023-12-31","value":-211591925.48900002},{"period":"2022-12-31","value":-52608451.497700006}],"eps":-0.2692,"epsHistory":[{"period":"2025-12-31","value":-0.2692},{"period":"2024-12-31","value":-41.75},{"period":"2023-12-31","value":-1.6311},{"period":"2022-12-31","value":-0.4129}],"cash":130166182.67240001,"cashHistory":[{"period":"2025-12-31","value":130166182.67240001},{"period":"2024-12-31","value":81484857.965},{"period":"2023-12-31","value":139345152.9876},{"period":"2022-12-31","value":189820085.0385}],"totalAssets":437611977.7659,"totalLiabilities":314886242.63530004,"totalDebt":199013834.1408,"equity":122725735.1306,"operatingCashflow":681167.7327,"operatingCashflowHistory":[{"period":"2025-12-31","value":681167.7327},{"period":"2024-12-31","value":-68071093.38260001},{"period":"2023-12-31","value":-38313333.7937},{"period":"2022-12-31","value":-16948581.7515}],"capex":-6396527.7621,"capexHistory":[{"period":"2025-12-31","value":-6396527.7621},{"period":"2024-12-31","value":-10071071.6456},{"period":"2023-12-31","value":-13209548.6152},{"period":"2022-12-31","value":-21894101.325600002}],"freeCashflow":-5715360.0294,"dividendsPaid":null,"buybacks":null,"employees":977,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":619,"previousClose":630,"fiftyTwoWeekHigh":962,"fiftyTwoWeekLow":288.5,"fiftyTwoWeekRange":"288.5 - 962.0","fiftyDayAverage":608.12,"twoHundredDayAverage":636.84,"beta":1.09,"enterpriseValue":1090901060.221504,"forwardPE":46,"priceToBook":8.19,"priceToSales":4.44,"enterpriseToRevenue":4.81,"enterpriseToEbitda":-44.46,"pegRatio":0,"ebitda":-24535473.6382,"ebitdaMargin":-10.8,"freeCashflow":-17801.720825,"operatingCashflow":681167.7327,"totalDebt":199013834.1408,"debtToEquity":162.2,"currentRatio":2.2,"returnOnAssets":-7,"returnOnEquity":-40.4,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":842.86,"targetHighPrice":1170,"targetLowPrice":550,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":20.8,"institutionHeldPercent":55.2,"sharesOutstanding":120919218,"floatShares":60801531,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.27,"epsForward":0.13,"revenuePerShare":1.51,"bookValue":0.76,"officers":[{"age":63,"name":"Dr. Frank  Mathias","title":"CEO & Director"},{"age":46,"name":"Dr. Lucinda Clair Crabtree Ph.D.","title":"CFO & Director"},{"age":null,"name":"Ms. Sophia  Bolhassan","title":"Head of Investor Relations"},{"age":52,"name":"Ms. Natalie Louise Walter","title":"Chief Legal Officer & Company Secretary"},{"age":null,"name":"Ms. Lisa  Doman","title":"Chief People Officer"},{"age":null,"name":"Dr. Kyriacos  Mitrophanous Ph.D.","title":"Chief Innovation Officer"},{"age":null,"name":"Ms. Kati  Hudson","title":"Head of Intellectual Property & Contracts"},{"age":null,"name":"Dr. Sebastien  Ribault","title":"Chief Business Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.oxb.com","phone":"44 1865 783 000"}}